96 related articles for article (PubMed ID: 10500835)
21. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
22. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
23. A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
Yang GS; McCulloch EA
Hematol Pathol; 1992; 6(3):125-30. PubMed ID: 1385380
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.
Hu ZB; Yang GS; Li M; Miyamoto N; Minden MD; McCulloch EA
Leukemia; 1995 May; 9(5):789-98. PubMed ID: 7769841
[TBL] [Abstract][Full Text] [Related]
25. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
26. Fluorescence-labeling of nicks in DNA from leukemic blast cells as a measure of damage following cytosine arabinoside. Application to the study of regulated drug sensitivity.
Yang GS; Wang C; Minden MD; McCulloch EA
Leukemia; 1994 Dec; 8(12):2052-9. PubMed ID: 7807994
[TBL] [Abstract][Full Text] [Related]
27. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
[TBL] [Abstract][Full Text] [Related]
28. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
Haldane A; Finlay GJ; Baguley BC
Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
[TBL] [Abstract][Full Text] [Related]
30. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.
Klumper E; Pieters R; Kaspers GJ; Huismans DR; Loonen AH; Rottier MM; van Wering ER; van der Does-van den Berg A; Hählen K; Creutzig U
Leukemia; 1995 Nov; 9(11):1864-9. PubMed ID: 7475276
[TBL] [Abstract][Full Text] [Related]
31. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
32. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture.
Fountzilas G; Inoue S; Ohnuma T
Leukemia; 1990 May; 4(5):321-4. PubMed ID: 2388478
[TBL] [Abstract][Full Text] [Related]
33. Is in vitro sensitivity of blast cells correlated to therapeutic effect in childhood acute lymphoblastic leukemia?
Frost BM; Larsson R; Nygren P; Lönnerholm G
Adv Exp Med Biol; 1999; 457():423-8. PubMed ID: 10500818
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
te Boekhorst PA; Löwenberg B; Sonneveld P
Leukemia; 1994 Sep; 8(9):1480-6. PubMed ID: 7522289
[TBL] [Abstract][Full Text] [Related]
36. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
37. In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
Hubeek I; Peters GJ; Broekhuizen R; Zwaan CM; Kaaijk P; van Wering ES; Gibson BE; Creutzig U; Janka-Schaub GE; den Boer ML; Pieters R; Kaspers GJ
Haematologica; 2006 Jan; 91(1):17-23. PubMed ID: 16434366
[TBL] [Abstract][Full Text] [Related]
38. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.
Nahi H; Lehmann S; Bengtzen S; Jansson M; Möllgård L; Paul C; Merup M
Leuk Lymphoma; 2008 Mar; 49(3):508-16. PubMed ID: 18297528
[TBL] [Abstract][Full Text] [Related]
39. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity.
Koistinen P; Wang C; Curtis JE; McCulloch EA
Leukemia; 1991 Sep; 5(9):789-95. PubMed ID: 1719308
[TBL] [Abstract][Full Text] [Related]
40. Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia.
Lishner M; Curtis JE; Minkin S; McCulloch EA
Leukemia; 1989 Nov; 3(11):784-8. PubMed ID: 2811479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
